BOSTON--(BUSINESS WIRE)-ClinicalStudyDataRequest.com (CSDR), a cross-industry initiative providing researchers with access to clinical trial data from 13 major pharmaceutical companies, including trials that involve multiple sponsors, has increased the number of trials available to more than 3,460.
The available trials span all major disease areas. For example, there are over 360 diabetes and 240 asthma trials listed. Since the initiative was launched, there have been 335 requests from researchers for trial data.
CSDR offers medical and scientific researchers an array of clinical trial data to facilitate collaboration, advance scientific knowledge, and improve outcomes for patients. Through this portal, researchers can request anonymized patient-level data from the list of clinical trials via an independent process managed by the Wellcome Trust.
“CSDR is proud to have reached these important milestones toward our goal of promoting scientific research by giving access to detailed, patient-level data. We are increasing the number of trials listed and making it easier to access the data. A further critical step this fall will be the unveiling of an enhanced web portal for researchers,” said Scott Martin, chair of the ClinicalStudyDataRequest.com Steering Committee.
Contact
KMR Group
Scott Martin
312.795.0400
smartin@kmrgroup.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.